Pfenex Inc. announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea in South Korea, JAMP Pharma in Canada and Kamada Ltd. in Israel. Furthermore, Alvogen’s partner in the Middle East and North Africa (MENA) region, SAJA, submitted a Marketing Authorization Application (MAA) to the Kingdom of Saudi Arabia'sSaudi Food and Drug Authority (SFDA). Additionally, the accepted MAA for PF708 under review by the European Medicines Agency (EMA) continues to make progress and Pfenex believes that PF708 could be approved in the European Union (EU) as early as the second half of 2020, pending marketing authorization by the European Commission under the EU centralized procedure and other factors. Subject to applicable regulatory approvals, PF708 will be commercialized by PharmBio Korea in Korea, JAMP Pharma in Canada, and Kamada in Israel. Under the terms of the agreements, Alvogen will be responsible for overseeing the local activities through PharmBio Korea, JAMP Pharma and Kamada. Pfenex will be eligible to receive milestone payments and a percentage of net sales or transfer price.